Vaxcyte to Raise $1B Through Equity and Convertible Note Offerings
Key Facts
Vaxcyte announced a public offering of $500 million in common stock and pre-funded warrants, Seeking Alpha reported. The company also plans to issue $500 million in convertible senior notes due in 2032, bringing the total capital raise to $1 billion.
The capital raise is intended to fund ongoing operations and development following a stock price surge triggered by positive vaccine trial results. PCVX closed at $56.48 on October 2, 2026, having traded between a day low of $55.84 and a high of $57 during that session.
Latest Updates · 2
- Notable·
Update: Vaxcyte's share price declined following the announcement of the dual $1 billion stock and note offering. The price movement reflects the initial market reaction to the new financing plan intended to bolster liquidity and project development.
- Notable·
Update: Vaxcyte stock price declined following the formal launch of the $1 billion dual offering. This pullback follows a recent surge in the share price that had been driven by positive vaccine trial results.